MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202521110106 A) filed by Rupali Bhawsar; and Dr. Kratika Daniel, Indore, Madhya Pradesh, on Nov. 12, 2025, for 'a novel herbal composition comprising flavonoid compounds isolated from drimiopsis kirkii leaves for treatment of peptic ulcer and related gastric disorders.'
Inventor(s) include Rupali Bhawsar; and Dr. Kratika Daniel.
The application for the patent was published on Dec. 12, under issue no. 50/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a novel pharmaceutical composition comprising bioactive flavonoid compounds, specifically quercetin and luteolin, isolated from the leaves of Drimiopsis kirkii Lindl. & Paxton (Synonym: Ledebouria socialis Roth.), family Hyacinthaceae, for the treatment and prevention of peptic ulcer disease and related gastric disorders. The composition exhibits potent anti-ulcer activity with ulcer inhibition of 60-78%, anti-secretory activity characterized by reduction in gastric juice volume and acidity, gastroprotective effects demonstrated by histopathological healing, antimicrobial activity against ulcer-associated pathogens, and COX-2 inhibitory activity. The isolated quercetin (C1) and luteolin (C2) compounds, as well as ethanol extract (EEDKL) and ethyl acetate extract (EAEDKL) of Drimiopsis kirkii leaves, showed significant therapeutic efficacy in aspirin-induced and pylorus ligation-induced ulcer models in rats, comparable to the standard drug omeprazole. The composition is safe with LD50 2000 mg/kg and can be formulated in various dosage forms including tablets, capsules, and syrups for oral administration. The invention provides an effective, safe, and affordable herbal alternative for the management of peptic ulcer disease with minimal adverse effects."
Disclaimer: Curated by HT Syndication.
